Product Description
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer[1][2].
[accordions]
[accordion title= “Biological Description“]
Description | Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer[1][2]. |
In vitro | Trastuzumab emtansine (2 μg/mL; 3 d) significantly inhibits the proliferation of epithelial ovarian cancer (EOC) cells[2]. |
In vivo | Trastuzumab emtansine (15 mg/kg; i.v. three to five times weekly for 3 weeks) exhibits significantly anti-tumor effect in mice[2]. Animal Model: CB-17/SCID mice (6 weeks) were injected with OVA10 cells[2] |
[/accordion]
[accordions]
[accordion title= “Chemical Properties“]
Molecular Weight | N/A |
Formula | N/A |
CAS No. | 1018448-65-1 |
[/accordion]
[accordions]
[accordion title= “References and Literature“]
1. Verma S, et, al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783-91.2. Menderes G, et, al. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecol Oncol. 2017 Oct;147(1):145-152.
[/accordion]